Open invitationA hackathon on my case. Wed 25 November, 5–6pm UK, online. Oncologists, radiologists, genomics people, vaccine researchers — come and pull my data apart.Details & RSVP →
For clinicians

Clinician brief

Half a page, built to be read before an appointment. If something here would not change a clinical decision or the next conversation, it is not on it. The full record, source documents and structured data sit behind the links at the bottom.

Version 2026-11-13 · One View v1.6
Current as of 13 November 2026
Next review repeat bloods 25 Nov · telephone with CT 8 Dec, before C9

Diagnosis

Moderately differentiated adenocarcinoma, rectosigmoid colon. ypT4a ypN1b (3/24 nodes) M1a V+. Treatment began Dec 2021; primary resected Mar 2022.
Sites of disease Lungs · mediastinal lymph nodes · liver segment VII (new, Jul 2026).
Also Smouldering myeloma (diagnosed end of 2021, under haematology surveillance); Gilbert's syndrome (can raise bilirubin). Original pathology Clinician letter

Molecular

KRAS/NRAS wild-type · BRAF wild-type · pMMR / MSS · HER2 IHC 0 · TMB-low · 3 Mut/Mb · PD-L1 <1% (22C3, 28-8)
Key detected tumour alterations APC p.S1415Rfs*4; TP53 p.R342* Commercial sequencing
Platform Oncomine Comprehensive Plus, 517-gene targeted panel, hg19. Not whole genome or whole exome. Reported tumour-only.

Treatment lines

Dec 21–Feb 22Neoadjuvant XELOX ×4 · good partial response
Mar–Oct 22Primary resected · liver met resected (R0) · adjuvant CAPOX
Oct 22–Apr 23Lung mets appear, progress · SABR 55 Gy/5
Jun & Aug 24Lung ablations (1 left, then 1 left + 4 right)
Feb 25EBUS confirms mediastinal nodal disease
Apr–Jul 25FOLFIRI + cetuximab ×6 · good partial response
Feb–May 26Rechallenge ×6 · good response (CT 12 May)
Jul–Aug 26Progression during the break · FOLFIRI + cetuximab restarted 19 Aug
Clinician letter

Current regimen

FOLFIRI + cetuximab (rechallenge, 3rd block), 14 days cycles. Plan: 8–12 weeks, then consider maintenance 5-FU + cetuximab if response is good. C7 given 12 Nov 2026 without irinotecan — first maintenance cycle; cold cap and erythromycin also stopped, dexamethasone shortened to the two days after infusion. C5 14 Oct, C6 29 Oct. Restaging CT 28 Oct: partial response at all known sites. Per the clinic letter of 2 Nov 2026: omit irinotecan from cycle 7 and continue maintenance modified de Gramont + cetuximab to disease progression, to de-intensify while maintaining control, given the short progression-free interval in the last treatment break. Local treatment not indicated — symptoms improved on chemotherapy, further ablation or radiotherapy would risk worsening breathing with no survival benefit, and the liver responded too. At progression: irinotecan could be added back, then Lonsurf + bevacizumab, then clinical trials, then fruquintinib. Oxaliplatin excluded (progression 2022, severe reaction).
Chemo dayStandard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after
SupportiveDexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN
OtherCitalopram 30 mg (breakfast) · melatonin 60 mg (evening) · metformin MR 500 mg twice daily (from cycle 5 day 7) · loratadine 10 mg
Not currently taking Mistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice Patient-reported

Off-label and adjuncts

Now taking metformin, mebendazole and atorvastatin, alongside melatonin.
As at 2 November 2026 · Status Disclosed to my oncologist at the 2 Nov review; she confirmed these can be taken alongside the chemotherapy. Originally proposed by my integrative oncologist (private). Clinician letter

Latest imaging

28 Oct 2026 · CT chest, abdomen & pelvis, compared with July 2026: partial response of the intrathoracic lymph nodes and lung metastases. Multiple hilar and parenchymal lung nodules partially reduced; a right upper lobe nodule has cavitated. Mediastinal nodes smaller, including subcarinal and left AP window. Atelectasis unchanged, no pleural effusion. Liver segment VII low density potentially minimally reduced, overall stable. No peritoneal disease, ascites or abdominopelvic lymphadenopathy. Skeleton unchanged.
Before that 23 Jul 2026 CT: progression above and below the diaphragm, new liver metastasis · 19 Jun 2026 CT head with contrast: normal · 12 May 2026 CT: good response · 6 Jan 2026 CT: progression. Imaging report

CEA

23 Jul 26 49.4 · 07 Aug 26 87.6 · 01 Sep 26 146 · 14 Sep 26 50.9 · 29 Sep 26 44.6 · 12 Oct 26 47.3 · 28 Oct 26 46.5 · 11 Nov 26 104.0 ug/L, ref 0–5.2 Laboratory bloods

Bloods out of range

11 November 2026: CEA 104.0 ug/L (high, ref 0–5.2, up from 46.5 on 28 Oct) · ALP 166 U/L (high, ref 30–130, up from 149) · Red cells 4.31 ×10¹²/L (low, ref 4.40–5.80) · Haemoglobin 133, platelets 328, bilirubin 10, ALT 39, AST 30, albumin 42 — in range. White cells 9.92 and neutrophils 7.16 in range but up from 6.46 and 3.28 on 28 Oct Laboratory bloods

Current plan and open questions

  • CEA more than doubled within two weeks of a partial response on CT — 46.5 on 28 Oct, 104.0 on 11 Nov, after sitting at 44–47 since late September. ALP also up, 149 to 166. What is the significance, and does it change the planned Christmas break? Repeat bloods 25 Nov.
  • Maintenance since C7 (12 Nov): modified de Gramont + cetuximab to disease progression, irinotecan omitted after the partial response. The UGT1A1 *28/*28 result is part of why.
  • Does 5-FU + bevacizumab before Lonsurf keep antibody–drug conjugate trials open?
  • Liver lesion local treatment — to revisit at the next scan.
  • NGS blood test results, once funding is confirmed.
  • Which alteration is the driving event? The panel reports APC p.S1415Rfs*4 and TP53 p.R342* as detected, but it does not designate a driver and no clinician has characterised one on my file. If a driver were formally called, would it change anything actionable?
  • NHS whole genome sequencing referral — the testing to date is a 517-gene panel, not WGS or WES.
  • Matched tumour/normal sequencing — the tumour panel is reported tumour-only.

Treating team

Primary oncologist — Consultant clinical oncologist, Bath Clinic; Haematologist — Consultant haematologist, Bath Clinic (smouldering myeloma); Integrative — Integrative oncologist (private), separate from my NHS/Bath Clinic team
Named identifiers are not published here. A version carrying them is sent to clinicians directly on request.

Patient-maintained, checked against source documents. Not medical advice. Sequencing — tumour DNA and RNA, liquid biopsy, germline and exosomal transcriptome, Astron / EXACTA (Astron Health), August 2025 — is set out in full, with the raw variant files, at fcancerwith.ai/full-record. Germline data is not published openly.
Full record: fcancerwith.ai/full-record · Structured data: /data/oneview.json · Corrections: fcancerwith.ai/corrections